|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-5-2
|
|
pubmed:abstractText |
Low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target in the National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines. This study tested the hypothesis that ezetimibe/simvastatin, a lipid-lowering agent that inhibits both intestinal cholesterol absorption and cholesterol synthesis, provides greater LDL-C reductions than atorvastatin across dose ranges.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
149
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
464-73
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15864235-Adult,
pubmed-meshheading:15864235-Aged,
pubmed-meshheading:15864235-Anticholesteremic Agents,
pubmed-meshheading:15864235-Azetidines,
pubmed-meshheading:15864235-C-Reactive Protein,
pubmed-meshheading:15864235-Cholesterol, HDL,
pubmed-meshheading:15864235-Cholesterol, LDL,
pubmed-meshheading:15864235-Double-Blind Method,
pubmed-meshheading:15864235-Drug Therapy, Combination,
pubmed-meshheading:15864235-Female,
pubmed-meshheading:15864235-Humans,
pubmed-meshheading:15864235-Hypercholesterolemia,
pubmed-meshheading:15864235-Male,
pubmed-meshheading:15864235-Middle Aged,
pubmed-meshheading:15864235-Simvastatin
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
|
|
pubmed:affiliation |
Department of Medicine, Baylor College of Medicine, Houston, Tex, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
